Orserdu (Elacestrant)

Elacestrant, the active ingredient in Orserdu, is a selective estrogen receptor degrader (SERD) presented as a 200 mg oral tablet for oral use. It treats estrogen receptor‑positive (ER+) advanced or metastatic breast cancer in adult patients. GNH USA supplies Orserdu as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Orserdu as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Orserdu is a hormone‑therapy agent that targets estrogen‑driven breast cancer pathways.

- Estrogen receptor‑positive advanced breast cancer: helps control disease progression in patients with metastatic or locally advanced ER+ tumors. - Hormone‑resistant disease: provides an oral option when tumors have progressed on prior endocrine therapies. - Post‑menopausal patients: offers a non‑injectable treatment alternative for eligible women with ER+ disease.

Adverse reactions reported with oral SERDs may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or lack of energy. - Diarrhea: loose stools, often transient. - Hot flashes: sudden feeling of warmth. - Decreased appetite: reduced desire to eat. - Musculoskeletal pain: aches in joints or muscles.

Serious or Rare Side Effects: - Liver enzyme elevation: significant increase in ALT/AST. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, swelling, or anaphylaxis. - QT interval prolongation: cardiac conduction changes on ECG. - Interstitial lung disease: inflammation of lung tissue. - Hyperglycemia: elevated blood glucose levels.

Patients should be evaluated for safety before starting therapy and monitored throughout treatment.

- Baseline labs: obtain liver function tests and electrolytes prior to initiation. - Cardiac monitoring: perform ECG if patient has risk factors for QT prolongation. - Pregnancy: avoid use; drug is contraindicated in pregnancy due to unknown fetal risk. - Concomitant hormones: assess interactions with other endocrine agents. - Renal impairment: adjust monitoring in patients with reduced kidney function. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Elacestrant may interact with other medicines that affect its metabolism or cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase elacestrant exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - QT‑prolonging drugs (e.g., sotalol, quinidine): additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring. - Hormonal therapies (e.g., tamoxifen): potential pharmacodynamic overlap. - Statins metabolised by CYP3A4 (e.g., atorvastatin): monitor for increased statin levels. - Proton pump inhibitors: may modestly affect absorption. - Herbal supplements (e.g., St St   ---